HypertensionPhase 2VICTOR-HTNNCT07360275
A Study of VCT220 in Participants With Hypertension and Obesity or Overweight
A Phase 2 study testing VCT220 Tablet in people with Hypertension, run by Vincentage Pharma Co., Ltd at 2 sites in China.
Trial summary
The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hypertension
- What is being tested?
- VCT220 Tablet
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 160 participants
- Where
- 2 sitesChina
- Study dates
- 1 Mar 2026to 20 Dec 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female participants aged 18 to 75 years (inclusive) at the time of screening.
- Body mass index (BMI) ≥ 24 kg/m² at screening.
- Diagnosed with primary hypertension, with office seated systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg at both screening and baseline.
- Either treatment-naïve to antihypertensive therapy for ≥ 30 days prior to screening, or receiving a stable dose for ≥ 30 days of one or two of the following classes of antihypertensive medications: renin-angiotensin system inhibitors (ARB/ACEI), calcium channel blockers (CCB), or diuretics.
- Has at least one self-reported history of unsuccessful weight loss through dietary control.
- Willing and able to maintain a stable residence and remain contactable throughout the study, and to adhere to regular lifestyle routines as well as dietary and exercise management during the trial.
- Has a full understanding of the study procedures, is able to communicate effectively with the investigator, understands and is willing to comply with all study requirements, and voluntarily provides written informed consent.
Who cannot join
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
- History of or current secondary hypertension.
- Office seated systolic blood pressure (SBP) ≥ 170 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg at screening or baseline, or presence of a hypertensive emergency.
- A decrease in office seated SBP of ≥ 20 mmHg or a decrease in office seated DBP of ≥ 10 mmHg at baseline compared with screening.
- Presence of orthostatic hypotension at screening, defined as a decrease in office SBP of ≥ 15 mmHg or DBP of ≥ 7 mmHg upon transition from the seated to standing position.
- A difference of ≥ 20 mmHg in office seated SBP between the left and right upper arms at screening or baseline.
Show all 15Show fewer
- Treatment with any marketed or investigational drug with a glucagon-like peptide-1 (GLP-1) receptor agonist mechanism within 1 year prior to screening.
- Self-reported or documented body weight change of ≥ 5 kg within 3 months prior to screening.
- History of or current type 1 or type 2 diabetes mellitus.
- History of or current malignancy within the past 5 years, except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- History of or current major cardiovascular or cerebrovascular disease.
- History of or current severe gastrointestinal disease or prior major gastrointestinal surgery.
- Clinically significant active or unstable severe major depressive disorder or other severe psychiatric disorders within 2 years prior to screening; or any history of suicide attempt.
- Patient Health Questionnaire-9 (PHQ-9) score ≥ 15 at screening, or a positive response to Item 9.
- Pregnant or breastfeeding women; or men or women of childbearing potential who are unwilling to use highly effective contraception throughout the study and for 3 months after the last dose, or who plan to conceive, donate sperm, or donate oocytes during this period; or women with a positive pregnancy test at screening.
Trial locations and contacts
2 sites in 1 country.
China2 sites
Beijing Luhe Hospital
Beijing, Beijing Municipality, 100044
Peking University People's Hospital
Beijing, Beijing Municipality, 100044
About this study
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of VCT220 in Participants With Hypertension and Obesity or Overweight.
The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.
- Conditions
- Hypertension
- Being tested
- VCT220 Tablet, VCT220 Placebo Tablet
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VCT220 TabletDrug
Administered orally, with or without food.
VCT220 Placebo TabletDrug
Administered orally, with or without food.
| Study group | Role | What they receive |
|---|---|---|
| VCT220 80mg | Experimental | Participants will receive VCT220 orally everyday. Starting from 20mg and maintaining at 80mg Receives: Drug: VCT220 Tablet |
| Placebo | Placebo comparator | Participants will receive placebo orally. Receives: Drug: VCT220 Placebo Tablet |
| VCT220 160mg (1) | Experimental | Participants will receive VCT220 orally everyday. Starting from 20mg and maintaining at 160mg Receives: Drug: VCT220 Tablet |
| VCT220 160mg (2) | Experimental | Participants will receive VCT220 orally everyday. Starting from 40mg and maintaining at 160mg Receives: Drug: VCT220 Tablet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in office seated systolic blood pressure (SBP) at Week 20
Measured In mmHg
Measured: From baseline to week 20
Secondary outcomes (6)
Change from baseline in office seated diastolic blood pressure (DBP) at Week 20
Measured in mmHg
Measured: From baseline to week 20
Change from baseline in 24-hour ambulatory blood pressure monitoring (ABPM) systolic blood pressure and diastolic blood pressure at Week 20
Measured in mmHg
Measured: From baseline to week 20
Proportion of participants achieving the standard blood pressure target (< 140/90 mmHg) based on office seated blood pressure at Week 20
Measured in percentage
Measured: From baseline to week 20
Proportion of participants achieving the intensive blood pressure target (< 130/80 mmHg) based on office seated blood pressure at Week 20
Measured in percentage
Measured: From baseline to week 20
Changes in body weight at week 20
Measured in Kg
Measured: From baseline to week 20
Adverse events, including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs)
Count of events
Measured: From baseline to week 20
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2026
- Study start1 Mar 2026
- Primary completion30 Oct 2026 (estimated)
- Study completion20 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 160 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vincentage Pharma Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07360275
- Sponsor's protocol ID
- VCT220-II-03
- Acronym
- VICTOR-HTN
- Status last verified
- Sep 2026
- First submitted
- 9 Jan 2026
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of VCT220 in Participants With Hypertension and Obesity or Overweight.
- ClinicalTrials.gov ID
- NCT07360275
- Acronym / sponsor ID
- VICTOR-HTN / VCT220-II-03
- Conditions
- Hypertension
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 160 participants (estimated)
- Lead sponsor
- Vincentage Pharma Co., LtdIndustry (pharma, biotech, devices)
- Study start
- 1 Mar 2026 (actual)
- Primary completion
- 30 Oct 2026 (estimated)
- Study completion
- 20 Dec 2026 (estimated)
- First posted
- 22 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| VCT220 80mg | Experimental | Drug: VCT220 TabletParticipants will receive VCT220 orally everyday. Starting from 20mg and maintaining at 80mg |
| Placebo | Placebo comparator | Drug: VCT220 Placebo TabletParticipants will receive placebo orally. |
| VCT220 160mg (1) | Experimental | Drug: VCT220 TabletParticipants will receive VCT220 orally everyday. Starting from 20mg and maintaining at 160mg |
| VCT220 160mg (2) | Experimental | Drug: VCT220 TabletParticipants will receive VCT220 orally everyday. Starting from 40mg and maintaining at 160mg |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Male or female participants aged 18 to 75 years (inclusive) at the time of screening.
- Body mass index (BMI) ≥ 24 kg/m² at screening.
- Diagnosed with primary hypertension, with office seated systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg at both screening and baseline.
- Either treatment-naïve to antihypertensive therapy for ≥ 30 days prior to screening, or receiving a stable dose for ≥ 30 days of one or two of the following classes of antihypertensive medications: renin-angiotensin system inhibitors (ARB/ACEI), calcium channel blockers (CCB), or diuretics.
- Has at least one self-reported history of unsuccessful weight loss through dietary control.
Key exclusion criteria (15 listed)
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
- History of or current secondary hypertension.
- Office seated systolic blood pressure (SBP) ≥ 170 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg at screening or baseline, or presence of a hypertensive emergency.
- A decrease in office seated SBP of ≥ 20 mmHg or a decrease in office seated DBP of ≥ 10 mmHg at baseline compared with screening.
- Presence of orthostatic hypotension at screening, defined as a decrease in office SBP of ≥ 15 mmHg or DBP of ≥ 7 mmHg upon transition from the seated to standing position.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VCT220 TabletAdministered orally, with or without food. | Drug | VCT220 160mg (1), VCT220 160mg (2), VCT220 80mg |
| VCT220 Placebo TabletAdministered orally, with or without food. | Drug | Placebo |
Primary outcome
Change from baseline in office seated systolic blood pressure (SBP) at Week 20
Time frame: From baseline to week 20
Measured In mmHg
6 secondary outcomes
Change from baseline in office seated diastolic blood pressure (DBP) at Week 20
Time frame: From baseline to week 20
Change from baseline in 24-hour ambulatory blood pressure monitoring (ABPM) systolic blood pressure and diastolic blood pressure at Week 20
Time frame: From baseline to week 20
Proportion of participants achieving the standard blood pressure target (< 140/90 mmHg) based on office seated blood pressure at Week 20
Time frame: From baseline to week 20
Proportion of participants achieving the intensive blood pressure target (< 130/80 mmHg) based on office seated blood pressure at Week 20
Time frame: From baseline to week 20
Changes in body weight at week 20
Time frame: From baseline to week 20
Adverse events, including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs)
Time frame: From baseline to week 20
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing VCT220 Tablet in people with Hypertension, run by Vincentage Pharma Co., Ltd at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in office seated systolic blood pressure (SBP) at Week 20 (time frame: From baseline to week 20). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.